These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

8054 related articles for article (PubMed ID: 2195120)

  • 21. Demonstration of 3-methoxytyrosine in the urine of melanoma patients.
    Agrup G; Bengtsson M; Falck B; Persson K; Rorsman H; Rosengren AM; Rosengren E
    Acta Derm Venereol; 1976; 56(1):27-31. PubMed ID: 56853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes.
    Rodeck U; Melber K; Kath R; Menssen HD; Varello M; Atkinson B; Herlyn M
    J Invest Dermatol; 1991 Jul; 97(1):20-6. PubMed ID: 2056188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cancer-related urinary proteinase inhibitor, EDC1: a new method for its isolation and evidence for multiple forms.
    Chawla RK; Lawson DH; Ahmad M; Travis J
    J Cell Biochem; 1992 Nov; 50(3):227-36. PubMed ID: 1469060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stimulation of prostaglandin E2 production by interleukin-1 alpha and transforming growth factor alpha in osteoblastic MC3T3-E1 cells.
    Harrison JR; Lorenzo JA; Kawaguchi H; Raisz LG; Pilbeam C
    J Bone Miner Res; 1994 Jun; 9(6):817-23. PubMed ID: 8079657
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Presence of growth factors in human pituitary.
    Halper J; Parnell PG; Carter BJ; Ren P; Scheithauer BW
    Lab Invest; 1992 May; 66(5):639-45. PubMed ID: 1573857
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced FHL2 and TGF-β1 Expression Is Associated With Invasive Growth and Poor Survival in Malignant Melanomas.
    Westphal P; Mauch C; Florin A; Czerwitzki J; Olligschläger N; Wodtke C; Schüle R; Büttner R; Friedrichs N
    Am J Clin Pathol; 2015 Feb; 143(2):248-56; quiz 307. PubMed ID: 25596251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [HPLC detection of pathologic metabolites of melanin and melatonin metabolism in the urine in malignant melanoma of the choroid].
    Dieckhues B
    Klin Monbl Augenheilkd; 1986 Jul; 189(1):34-5. PubMed ID: 3761975
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary TGFs1 in neoplasia: immunoreactive TGF-alpha in the urine of patients with disseminated breast carcinoma.
    Stromberg K; Hudgins WR; Orth DN
    Biochem Biophys Res Commun; 1987 Apr; 144(2):1059-68. PubMed ID: 3472521
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
    Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E
    Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Growth factor production by human colon carcinoma cell lines.
    Anzano MA; Rieman D; Prichett W; Bowen-Pope DF; Greig R
    Cancer Res; 1989 Jun; 49(11):2898-904. PubMed ID: 2541895
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a 15,000-molecular-weight form of immunoreactive transforming growth factor alpha in extracts of porcine pituitary.
    Riss TL; Sirbasku DA
    J Cell Physiol; 1989 Feb; 138(2):393-404. PubMed ID: 2918041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-S-cysteinyldopa in the urine of melanoma patients.
    Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
    Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Taqi RFLP of the human TGF alpha gene is significantly associated with cutaneous malignant melanoma.
    Hayward N; Nancarrow D; Ellem K; Parsons P; Kidson C
    Int J Cancer; 1988 Oct; 42(4):558-61. PubMed ID: 2902017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Occurrence of trichochromes in the urine of a melanoma patient.
    Prota G; Rorsman H; Rosengren AM; Rosengren E
    Experientia; 1976 Sep; 32(9):1122-4. PubMed ID: 971737
    [No Abstract]   [Full Text] [Related]  

  • 36. Differential effects of transforming growth factor beta 1 on the growth of poorly and highly metastatic murine melanoma cells.
    Mooradian DL; Purchio AF; Furcht LT
    Cancer Res; 1990 Jan; 50(2):273-7. PubMed ID: 2295066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using adenovirus armed short hairpin RNA targeting transforming growth factor β1 inhibits melanoma growth and metastasis in an ex vivo animal model.
    Tai KF; Wang CH
    Ann Plast Surg; 2013 Dec; 71 Suppl 1():S75-81. PubMed ID: 24284745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of transforming growth factor activity in effusions from cancer patients.
    Hanauske AR; Arteaga CL; Clark GM; Buchok J; Marshall M; Hazarika P; Pardue RL; Von Hoff DD
    Cancer; 1988 May; 61(9):1832-7. PubMed ID: 3162700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A case of dark urine, hyperpigmentation and hepatomegaly.
    McClements BM; McDowell IF; McCluskey DR
    Ir J Med Sci; 1988 May; 157(5):157. PubMed ID: 3225162
    [No Abstract]   [Full Text] [Related]  

  • 40. Evaluation of the clinical usefulness of measuring urinary excretion of 5-S-cysteinyldopa in melanoma: ten years' experience of 50 patients.
    Sasaki Y; Shimizu H; Naka W; Takeshita E; Nishikawa T
    Acta Derm Venereol; 1997 Sep; 77(5):379-81. PubMed ID: 9298132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 403.